Clinical characteristics of the Norwegian myasthenia gravis study cohort (n = 369).

1<p>According to MGFA classification <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0036603#pone.0036603-JaretzkiA1" target="_blank">[39]</a>: ocular MG (MGFA grade I), generalised MG (MGFA grade II-V), not available in 12 cases.</p>2<p>Concomitant immune-mediated diseases include thyroid disease (hypo-, hyperthyroidsm, thyroiditis), type 1-diabetes, rheumatic diseases, systemic lupus erythematosus (SLE), celiac disease, inflammatory bowel diseases (Crohńs disease or ulcerative colitits). EOMG = early onset MG; LOMG = late onset MG; AChR-ab+  =  acetylcholine receptor-antibody positive.</p

Conditional analyses of the HLA-A, -B, -C and DRB1 loci (p-values) in early onset myasthenia gravis (EOMG).

<p>P-values are not corrected, p<0.01 is considered significant after correction for multiple comparisons (n = 4).</p

The association between HLA loci and myasthenia gravis subgroups (p-values).

<p>EOMG = early onset MG, LOMG = late onset MG.</p><p>P-values are not corrected, p<0.01 is considered significant after correction for multiple comparisons (n = 4).</p

The most strongly associated HLA alleles in early onset myasthenia gravis (EOMG).

<p>Odds Ratio (OR) and 95% confidence interval (CI) are shown for nominal p-values.</p

Assessment of the strongest association on the HLA-B*08-DRB1*03:01 haplotype in early onset myasthenia gravis (EOMG).

<p>+  =  positives, −  =  negatives.</p

Associated alleles in late onset myasthenia gravis (LOMG).

<p>Odds Ratio (OR) and 95% confidence interval (CI) are shown for nominal p-values.</p

Schematic overview of associated HLA alleles in MG.

<p>The HLA complex on chromosome 6 with its division into three classes. Some key genes and their order on the chromosome are given. Associated HLA alleles reported earlier in Caucasian MG patients (see text for complete references) are illustrated together with the results from the present study.</p

Clinical characteristics of MS patients and association testing to OCB status.

<p><i>Abbreviations:</i><b>M</b> = Male, <b>F</b> = Female, <b>AAO</b> = Age at onset, <b>PP</b> = Primary progressive, <b>RR</b> = Relapsing remitting, <b>OCB</b> = Oligoclonal bands <b>EDSS</b> = Expanded Disability Status Scale, <b>MSSS</b> = Multiple Sclerosis Severity Score.</p>a<p>The p values for association between OCB status and the annotated clinical parameters.</p

Results of screening, replication and combined analyses of the nine SNPs brought forward to the replication.

*<p>Numbers included after quality control of genotyping data.</p><p><i>Abbreviations</i>: <b>CHR</b> = chromosome, <b>SNP</b> = single nucleotide polymorphism, <b>OR</b> = odds ratio, <b>CI</b> = confidence interval, <b>n</b> = number of individuals included in the analyses after quality control, <b><i>HNMT</i></b><i>: histamine N-methyltransferase, </i><b><i>CLSTN2</i></b><i> = Calsyntenin-2, </i><b><i>BTLN2</i></b><i> = Butyrophilin-like protein 2, </i><b><i>UTRN</i></b><i> = Utrophin, </i><b><i>FBXO25</i></b><i> = F-box protein 25.</i></p>a<p>Where a SNP is located within a gene, the corresponding gene is underlined.</p>b<p>The OR is given for OCB negative patients/OCB positive patients.</p>c<p>The p values are calculated setting age at onset to covariate and are uncorrected for multiple testing.</p

Subtypes of HLA-DRB1 alleles showing association to OCB positive and/or OCB negative MS in Norwegian MS patients and healthy controls.

<p><i>Abbreviations</i>: <b>n</b> = total Norwegian samples available with HLA-DRB1* genotypes of 4 digit solution, i.e. MS patients from the screening and replication are pooled, <b>OCB</b> = oligoclonal bands, <b>OR</b> = odds ratio, <b>CI</b> = confidence interval.</p>a<p>The results are only shown for alleles with frequencies >5%.</p>b<p>All p values are uncorrected for multiple testing.</p>c (<p>*¹⁵⁰¹⁾ p values after stratification for HLA-DRB1*15∶01.</p